Toronto Dominion Bank lessened its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 5.8% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 204,832 shares of the medical instruments supplier’s stock after selling 12,625 shares during the quarter. Toronto Dominion Bank owned about 0.07% of Becton Dickinson and worth $49,021,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the stock. Wellington Management Group LLP grew its position in shares of Becton Dickinson and by 225.4% during the 1st quarter. Wellington Management Group LLP now owns 8,473,220 shares of the medical instruments supplier’s stock valued at $1,946,892,000 after purchasing an additional 5,869,236 shares in the last quarter. FMR LLC increased its position in Becton Dickinson and by 35.7% during the 2nd quarter. FMR LLC now owns 12,360,686 shares of the medical instruments supplier’s stock valued at $2,957,540,000 after purchasing an additional 3,253,254 shares during the period. BlackRock Inc. lifted its holdings in Becton Dickinson and by 9.2% during the second quarter. BlackRock Inc. now owns 20,760,348 shares of the medical instruments supplier’s stock worth $4,967,327,000 after buying an additional 1,755,896 shares during the period. Flossbach Von Storch AG grew its stake in Becton Dickinson and by 334.5% in the first quarter. Flossbach Von Storch AG now owns 1,875,063 shares of the medical instruments supplier’s stock valued at $430,833,000 after purchasing an additional 1,443,558 shares during the last quarter. Finally, Mackenzie Financial Corp raised its stake in shares of Becton Dickinson and by 73.8% during the 1st quarter. Mackenzie Financial Corp now owns 2,652,092 shares of the medical instruments supplier’s stock worth $609,371,000 after acquiring an additional 1,126,373 shares in the last quarter. 84.18% of the stock is owned by institutional investors.

A number of research analysts have recently weighed in on BDX shares. Raymond James increased their price objective on Becton Dickinson and from $265.00 to $285.00 and gave the company an “outperform” rating in a report on Friday, August 7th. They noted that the move was a valuation call. Morgan Stanley lowered their price target on Becton Dickinson and from $285.00 to $270.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 27th. Zacks Investment Research lowered shares of Becton Dickinson and from a “hold” rating to a “sell” rating and set a $245.00 target price on the stock. in a research note on Wednesday, May 27th. William Blair reissued an “outperform” rating on shares of Becton Dickinson and in a research report on Thursday, July 2nd. Finally, SVB Leerink lifted their price objective on Becton Dickinson and from $262.00 to $277.00 and gave the company a “market perform” rating in a research note on Wednesday, July 15th. One analyst has rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $279.47.

Shares of BDX stock traded up $0.88 during trading hours on Wednesday, hitting $227.03. 129,935 shares of the company were exchanged, compared to its average volume of 1,464,388. The stock has a market capitalization of $68.38 billion, a price-to-earnings ratio of 82.14, a P/E/G ratio of 3.00 and a beta of 0.85. Becton Dickinson and Co has a one year low of $197.75 and a one year high of $286.72. The business’s 50-day simple moving average is $254.55 and its two-hundred day simple moving average is $247.51. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.97 and a current ratio of 1.45.

Becton Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.20 EPS for the quarter, topping the consensus estimate of $2.04 by $0.16. The company had revenue of $3.86 billion during the quarter, compared to analyst estimates of $3.96 billion. Becton Dickinson and had a return on equity of 14.19% and a net margin of 5.30%. The business’s revenue was down 11.4% on a year-over-year basis. During the same quarter last year, the firm earned $3.08 EPS. As a group, analysts anticipate that Becton Dickinson and Co will post 9.9 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 1.39%. The ex-dividend date is Tuesday, September 8th. Becton Dickinson and’s dividend payout ratio is presently 27.05%.

In other Becton Dickinson and news, EVP Patrick Kaltenbach sold 1,272 shares of the stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $260.00, for a total transaction of $330,720.00. Following the sale, the executive vice president now directly owns 10,340 shares of the company’s stock, valued at $2,688,400. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.12% of the stock is owned by insiders.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Story: Average Daily Trade Volume Explained

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.